Expand RLMD Menu
RLMD MENU

RLMD Latest Press Releases

-- March 19, 2026 --

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update Globe Newswire 4:01 PM

-- March 12, 2026 --

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 Globe Newswire 7:00 AM

-- March 9, 2026 --

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference Globe Newswire 4:30 PM
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing Globe Newswire 7:05 AM
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer Globe Newswire 7:00 AM

-- January 12, 2026 --

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications Globe Newswire 7:00 AM

-- December 3, 2025 --

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology Globe Newswire 7:30 AM

-- November 13, 2025 --

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates Globe Newswire 4:01 PM

-- November 7, 2025 --

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 Globe Newswire 7:30 AM

-- November 4, 2025 --

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Globe Newswire 7:09 AM
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer Globe Newswire 7:01 AM
Market Data Delayed 15 Minutes